

# Novavax enters late-stage clinical trials

September 25 2020

---



A vial with a potential coronavirus, COVID-19, vaccine at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19

US biotech firm Novavax said Thursday it was initiating its final Phase 3 clinical trial for its experimental COVID-19 vaccine.

The trial will be carried out in the United Kingdom and aims to enroll 10,000 volunteers, aged 18-84, with and without underlying conditions, over the next four to six weeks.

"With a high level of SARS-CoV-2 transmission observed and expected to continue in the UK, we are optimistic that this pivotal Phase 3 clinical trial will enroll quickly and provide a near-term view of NVX-CoV2373's efficacy," said Gregory Glenn, the company's president of research and development, using the technical name for the formulation.

It is the eleventh COVID-19 vaccine candidate to reach the Phase 3 stage globally.

The company has been awarded \$1.6 billion by the US government to develop and fund the drug, which is administered by two intramuscular injections.

The Maryland-based company uses [insect cells](#) to grow synthesized pieces of the spike protein of the virus, which it hopes will evoke a robust human immune response.

It also uses an "adjuvant," a compound that boosts the production of neutralizing antibodies.

The company says the drug, which is a liquid formulation, can be stored at two degrees celsius to eight degrees celsius, refrigerator temperature.

In the spring, the [company](#) said it had proven the efficacy of a seasonal flu vaccine it had developed using the same technology.

© 2020 AFP

Citation: Novavax enters late-stage clinical trials (2020, September 25) retrieved 23 January 2023

from <https://medicalxpress.com/news/2020-09-novavax-late-stage-clinical-trials.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.